Update on Early-Stage Studies of Novel Treatments in Glioblastoma

From The ASCO Post

Read the Full Article

Outcomes are typically grim for patients with recurrent glioblastoma multiforme. At the 2019 Annual Scientific Meeting of the American Association of Neurological Surgeons (AANS), three early-stage studies hinted at ways that standard treatments might be made more effective.

Metronomic Dosing of Temozolomide May Enhance Efficacy of Checkpoint Inhibition

The efficacy of temozolomide, when combined with checkpoint inhibition, may be enhanced by metronomic dosing, according to a study from University of Florida researchers and reported by Maryam Rahman, MD, MS, of the Brain Tumor Immunotherapy Program.

Continue Reading

About Dr. Maryam Rahman

Dr. Maryam Rahman Brain Tumor Immunotherapy Lab